[go: up one dir, main page]

WO2007127212A3 - Anti-viral agents that activate rnase l - Google Patents

Anti-viral agents that activate rnase l Download PDF

Info

Publication number
WO2007127212A3
WO2007127212A3 PCT/US2007/009959 US2007009959W WO2007127212A3 WO 2007127212 A3 WO2007127212 A3 WO 2007127212A3 US 2007009959 W US2007009959 W US 2007009959W WO 2007127212 A3 WO2007127212 A3 WO 2007127212A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral agents
activate rnase
rnase
activate
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/009959
Other languages
French (fr)
Other versions
WO2007127212A2 (en
Inventor
Robert Silverman
Paul Torrence
Babal Kant Jha
Paula Francom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Northern Arizona University
Original Assignee
Cleveland Clinic Foundation
Northern Arizona University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation, Northern Arizona University filed Critical Cleveland Clinic Foundation
Priority to AU2007243403A priority Critical patent/AU2007243403A1/en
Priority to EP07755981A priority patent/EP2016062A2/en
Priority to CA002650028A priority patent/CA2650028A1/en
Priority to JP2009507765A priority patent/JP2009536622A/en
Priority to MX2008013668A priority patent/MX2008013668A/en
Publication of WO2007127212A2 publication Critical patent/WO2007127212A2/en
Publication of WO2007127212A3 publication Critical patent/WO2007127212A3/en
Priority to IL194890A priority patent/IL194890A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

RNase L Activators and methods of using the same are disclosed herein.
PCT/US2007/009959 2006-04-25 2007-04-25 Anti-viral agents that activate rnase l Ceased WO2007127212A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2007243403A AU2007243403A1 (en) 2006-04-25 2007-04-25 Anti-viral agents that activate RNase L
EP07755981A EP2016062A2 (en) 2006-04-25 2007-04-25 Anti-viral agents that activate rnase l
CA002650028A CA2650028A1 (en) 2006-04-25 2007-04-25 Anti-viral agents that activate rnase l
JP2009507765A JP2009536622A (en) 2006-04-25 2007-04-25 Antiviral agent that activates RNase L
MX2008013668A MX2008013668A (en) 2006-04-25 2007-04-25 Anti-viral agents that activate rnase l.
IL194890A IL194890A0 (en) 2006-04-25 2008-10-23 ANTI-VIRAL AGENTS THAT ACTIVATE RNase L

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79506906P 2006-04-25 2006-04-25
US60/795,069 2006-04-25

Publications (2)

Publication Number Publication Date
WO2007127212A2 WO2007127212A2 (en) 2007-11-08
WO2007127212A3 true WO2007127212A3 (en) 2008-03-27

Family

ID=38374152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009959 Ceased WO2007127212A2 (en) 2006-04-25 2007-04-25 Anti-viral agents that activate rnase l

Country Status (10)

Country Link
EP (1) EP2016062A2 (en)
JP (1) JP2009536622A (en)
KR (1) KR20090007609A (en)
CN (1) CN101460471A (en)
AU (1) AU2007243403A1 (en)
CA (1) CA2650028A1 (en)
IL (1) IL194890A0 (en)
MX (1) MX2008013668A (en)
RU (1) RU2008146422A (en)
WO (1) WO2007127212A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009123588A1 (en) * 2008-04-01 2009-10-08 The Cleveland Clinic Foundation Amides of 3, 5-substituted-is0xaz0le-4-carb0xylic acids for the treatment of viral infections, cancer and restenosis
AU2010229144B2 (en) * 2009-03-23 2012-07-12 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
JP5890522B2 (en) 2011-08-05 2016-03-22 ビオタ サイエンティフィック マネージメント ピーティーワイ リミテッド Compounds for the treatment of respiratory syncytial virus infection
RU2487708C1 (en) * 2012-03-12 2013-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) Method of treating parvoviral infection b19 in infants
TWI472518B (en) * 2014-01-02 2015-02-11 Univ China Medical Use of derivative of aniline in anti-virus application
US20200055848A1 (en) * 2016-11-04 2020-02-20 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
CN109745311B (en) * 2019-02-22 2021-12-17 北京大学深圳研究生院 Application of RNase L enzyme inhibitor
CA3156387A1 (en) * 2019-10-29 2021-05-06 Matthew D. Disney Compounds and modules for inhibition of pre-mir-21 and their use in treatment of certain cancers
CN112107679A (en) * 2020-09-28 2020-12-22 武汉愔紫生物科技有限公司 Application of macromolecular protein in anti-RNA virus disinfectant
CN112088903A (en) * 2020-09-28 2020-12-18 武汉愔紫生物科技有限公司 Application of macromolecular protein in antibacterial and antiviral disinfectant

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047760A2 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Novel chemical compounds
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20050042213A1 (en) * 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2005082901A1 (en) * 2004-02-25 2005-09-09 Smithkline Beecham Corporation Novel chemical compounds
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047760A2 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Novel chemical compounds
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20050042213A1 (en) * 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
WO2005082901A1 (en) * 2004-02-25 2005-09-09 Smithkline Beecham Corporation Novel chemical compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TOLEDO-SHERMAN LETICIA ET AL: "Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening.", JOURNAL OF MEDICINAL CHEMISTRY 5 MAY 2005, vol. 48, no. 9, 5 May 2005 (2005-05-05), pages 3221 - 3230, XP002448944, ISSN: 0022-2623 *
TONGHUI MA ET AL: "High-Affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 40, 4 October 2002 (2002-10-04), pages 37235 - 37241, XP002327308, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2650028A1 (en) 2007-11-08
RU2008146422A (en) 2010-05-27
JP2009536622A (en) 2009-10-15
CN101460471A (en) 2009-06-17
KR20090007609A (en) 2009-01-19
AU2007243403A1 (en) 2007-11-08
EP2016062A2 (en) 2009-01-21
IL194890A0 (en) 2009-08-03
MX2008013668A (en) 2009-01-27
WO2007127212A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007127212A3 (en) Anti-viral agents that activate rnase l
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
EP2055100A4 (en) Method of controlling receiver and receiver using the same
WO2007146259A3 (en) Composite assembly and methods of making and using the same
CA119671S (en) Television receiver
WO2008046104A3 (en) Methods and systems for knowledge discovery
EP1759973B8 (en) Running object and method of controlling the same
WO2007140371A3 (en) Antibodies and immunoconjugates and uses therefor
WO2008085570A3 (en) Flux formulations
WO2005097825A3 (en) Bmp-7 variants with improved properties
IL211889A (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof as nadph oxidase inhibitors
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2007130873A3 (en) Liver-specific nanocapsules and methods of using
WO2008060795A3 (en) Antimicrobial articles and method of manufacture
WO2008027600A3 (en) Imatinib compositions
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2010057143A8 (en) Water-soluble multi-layer materials, articles made therefrom and methods of making and using the same
WO2006050341A3 (en) Modified streptococcal polysaccharides and uses thereof
WO2007149932A3 (en) Methods and compositions for targeting hepsin
CA117351S (en) Iron
WO2007016702A3 (en) Chimeric polymerases
WO2006089166A3 (en) Food serving arrangement
CA117204S (en) Iron
EP2056852A4 (en) Bmp-7 variant compositions, methods and uses
HK40101421A (en) Method of making an absorbent composite and absorbent articles employing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780020825.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755981

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2650028

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 194890

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009507765

Country of ref document: JP

Ref document number: MX/A/2008/013668

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007243403

Country of ref document: AU

Ref document number: 9558/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007755981

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008146422

Country of ref document: RU

Ref document number: 1020087028782

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007243403

Country of ref document: AU

Date of ref document: 20070425

Kind code of ref document: A